RxDoctor Payments Data

Michael Hoban, DO

Cardiovascular Disease · East Syracuse, NYNPI 1366893141

Payments from drug & device makers

$2,580in general payments, 2019–2025

Across 95 payments — averaging $27.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$457
  • Boston Scientific$250
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$220
  • Edwards Lifesciences$217
  • Amgen$199
  • AstraZeneca$192
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,43494%
  • Education$1466%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,580 in reported general payments places this provider in the 55th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$122,824
Medicare patients
1,216
Services billed
2,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$217,819
EntrestoSacubitril/Valsartan52$74,734
FarxigaDapagliflozin Propanediol39$41,272
JardianceEmpagliflozin28$38,796
XareltoRivaroxaban23$35,531
Repatha SureclickEvolocumab15$22,661
Praluent PenAlirocumab11$5,546
Atorvastatin Calcium285$2,574
Ranolazine ErRanolazine24$2,139
Metoprolol Succinate122$1,517
Ezetimibe79$1,211
Rosuvastatin Calcium122$1,045
Flecainide Acetate13$606
Amlodipine Besylate113$599
Losartan Potassium82$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$217,819155 claims
NovartisEntresto$457$74,73452 claims
AstraZenecaFarxiga$192$41,27239 claims
Boehringer IngelheimJardiance$59$38,79628 claims
Johnson & JohnsonXarelto$13$35,53123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →